[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:glucosidase-alpha-acid":3},{"name":4,"total":5,"recruiting":5,"trials":6},"GLUCOSIDASE, ALPHA, ACID",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07282847","A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:44.395098Z","2026-07-24T01:27:14.897996Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT07123155","Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)",[19],"Phase 2","2026-08-26T02:17:05.997056Z","2026-05-05T02:43:27.592142Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06121011","A Global Prospective Observational Registry of Patients With Pompe Disease",[],"2026-08-26T02:16:24.970704Z","2026-05-13T02:55:06.416937Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT00231400","Pompe Disease Registry Protocol",[],"2026-08-26T02:15:53.461103Z","2026-05-13T02:55:06.032941Z"]